Novo Nordisk initiates trial of new candidate against fatty liver disease
![Photo: Tidsvilde Stine/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/14599705/ymk515/ALTERNATES/schema-16_9/20160929-062240-pf-4924x2768ma%2520(1).jpg)
In November, Novo Nordisk began early-stage testing of drug candidate NNC0581-0001 against non-alcoholic fatty liver disease (NAFLD), according to a filing on the Clinical Trials database.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Altimmune meets NASH goal in phase I
For subscribers